Genetic Risk-Based Atrial Fibrillation Screening (GeneAF Study)

Enrolling by invitationOBSERVATIONAL
Enrollment

726

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

January 10, 2026

Study Completion Date

January 10, 2026

Conditions
Genetic PredispositionAtrial Fibrillation
Interventions
DIAGNOSTIC_TEST

Resting ECG (if first visit is done on site only)

"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."

DIAGNOSTIC_TEST

24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)

The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.

DIAGNOSTIC_TEST

3-month AF detection monitoring using the Apple Watch

Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

All Listed Sponsors
lead

Montreal Heart Institute

OTHER